DALRADA FINCL CORP - DFCO STOCK NEWS

Dalrada Financial Corporation (OTCQB: DFCO) has announced a new 10-year lease for a 20,000-square foot facility in Livingston, Scotland. This location will serve as the UK headquarters for Dalrada Technology Ltd., housing its subsidiaries Deposition Technology (DepTec) and Likido. The new site aims to enhance production capabilities for clean energy solutions and semiconductor technologies, catering to increasing global demand. CEO Brian Bonar emphasized the facility's significance in fostering innovation and cost efficiency. The move is expected to be completed by March 1.

Dalrada Financial Corporation (OTCQB: DFCO) has appointed Harvey Hershkowitz as chair and Pauline Gourdie as vice chair of its new health care division, Genefic. Hershkowitz has been a board member since July 2020, and Gourdie joined in August 2019. The board also includes four other members with extensive industry experience. Hershkowitz expressed excitement about leveraging technology for global health improvements. The management change is seen as a step towards enhancing leadership in health care innovations.

Dalrada Financial Corporation (OTCQB: DFCO) has appointed Harvey Hershkowitz as the Chairman and CEO of its new health division, Genefic, previously known as Dalrada Health. With nearly 40 years of experience in healthcare and business, Hershkowitz aims to enhance patient care through innovative technologies and products. His leadership is expected to drive growth and align with Dalrada's global vision. Brian Bonar, the founder, highlighted Hershkowitz's strategic insight and understanding of the industry as essential for Genefic's future success.

Dalrada Corporation (OTCQB: DFCO) has appointed MGO (Macias Gini and O’Connell LLP) as its new independent auditor starting from the quarter ending December 31, 2022. This decision is part of Dalrada's business transformation, aimed at aligning with its growing segments, especially in clean energy and precision manufacturing. The company has also reported strong triple-digit growth in the 2022 fiscal year, highlighting significant market demand and federal incentives for its new Dalrada Energy Services. The partnership with MGO is expected to support the company's ongoing expansion.

Dalrada Financial Corporation (OTCQB: DFCO) announces that its subsidiary, Empower Genomics, has received approval from the CDC to distribute and administer COVID-19 vaccines. This positions Empower Genomics alongside major pharmacies in serving at-risk populations in the San Diego area. The program includes Flu and COVID-19 vaccinations for various age groups. California has also granted funding to support these efforts, particularly for vaccinating infants and toddlers. Empower Genomics continues providing onsite COVID-19 testing and encourages online appointment bookings through the CDPH.

Dalrada Financial Corporation (OTCQB: DFCO) reported positive financial growth in its Q1 Fiscal 2023 results, generating $4.3 million in total revenue. Key revenue streams include Dalrada Health at $2.4 million and Precision Manufacturing at $1.1 million. The company is advancing its initiatives in green energy, particularly through contracts signed by Dalrada Energy Services, while also enhancing its digital capabilities via partnerships aimed at sustainable technology solutions. CEO Brian Bonar expressed a strong outlook for continued revenue growth in 2023.

Dalrada Financial Corporation (OTCBQ: DFCO) announced its Fiscal Year 2022 financial results, reporting total revenues of approximately $19.3 million, a dramatic 465% year-over-year growth compared to $3.4 million in FY 2021. Key segments showed strong performance: Dalrada Health rose 683% to $13.6 million, while Dalrada Precision Manufacturing increased by 341% to $2.1 million. The Company made significant acquisitions, including Watson RX Solutions, and launched new services, reinforcing its market presence in health care, energy, and technology sectors.

Dalrada Financial Corporation (OTCQB: DFCO) announced that its subsidiary, Deposition Technology, has secured a contract with the University of Arkansas to develop a new deposition system. This system aims to facilitate high-volume manufacturing of silicon carbide (SiC) devices. The Novellus C1 PECVD system will be remanufactured to the university's specifications for the Multi-User Silicon Carbide (MUSiC) Research facility, which focuses on bridging basic research and production processes.